Phaseline

Companies › Ascendis Pharma Bone Diseases

Ascendis Pharma Bone Diseases: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 3; Metabolic and endocrine; next expected readout Jun 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Palopegteriparatide
Parathyroid hormone receptor agonist
PTH1RPhase 3HypoparathyroidismJun 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07081997PalopegteriparatidePhase 3HypoparathyroidismMetabolic and endocrineJun 2027

Targets

PTH1R (1)

Companies with the same targets

Ascendis Pharma AstraZeneca

Companies built like this

BioXTek Ascendis Pharma Extend Biosciences PolarityTE Royal Biologics

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.